<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36618399</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets.</ArticleTitle><Pagination><StartPage>1059994</StartPage><MedlinePgn>1059994</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1059994</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1059994</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron damage. Due to the complexity of the ALS, so far the etiology and underlying pathogenesis of sporadic ALS are not completely understood. Recently, many studies have emphasized the role of inflammatory networks, which are comprised of various inflammatory molecules and proteins in the pathogenesis of ALS. Inflammatory molecules and proteins may be used as independent predictors of patient survival and might be used in patient stratification and in evaluating the therapeutic response in clinical trials. This review article describes the latest advances in various inflammatory markers in ALS and its animal models. In particular, this review discusses the role of inflammatory molecule markers in the pathogenesis of the disease and their relationship with clinical parameters. We also highlight the advantages and disadvantages of applying inflammatory markers in clinical manifestations, animal studies, and drug clinical trials. Further, we summarize the potential application of some inflammatory biomarkers as new therapeutic targets and therapeutic strategies, which would perhaps expand the therapeutic interventions for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Jiang, Wang, Wei and Yu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zongzhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xiaojing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xue-Fan</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">animal model</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>3</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36618399</ArticleId><ArticleId IdType="pmc">PMC9815501</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1059994</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol (2018) 17(5):423&#x2013;33. doi: 10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Goedee HS, Westeneng HJ, Nijboer TCW, van den Berg LH. Is it accurate to classify ALS as a neuromuscular disorder? Expert Rev Neurother (2020) 20(9):895&#x2013;906. doi: 10.1080/14737175.2020.1806061</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1806061</ArticleId><ArticleId IdType="pubmed">32749157</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol (2020) 27(10):1918&#x2013;29. doi: 10.1111/ene.14393</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropatholog (2019) 137(5):715&#x2013;30. doi: 10.1007/s00401-018-1933-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibaj P, Zsch&#xfc;ntzsch J, Steffens H, Scheffel J, G&#xf6;ricke B, Weishaupt JH, et al. . Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS. PloS One (2012) 7(8):e43963. doi:&#xa0;10.1371/journal.pone.0043963</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043963</ArticleId><ArticleId IdType="pmc">PMC3428282</ArticleId><ArticleId IdType="pubmed">22952827</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyken SJ, Locksley RM. Chitins and chitinase activity in airway diseases. J Allergy Clin Immunol (2018) 142(2):364&#x2013;9. doi: 10.1016/j.jaci.2018.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2018.06.017</ArticleId><ArticleId IdType="pmc">PMC6078791</ArticleId><ArticleId IdType="pubmed">29959948</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa M, Distefano G, Zorena K, Malaguarnera L. Chitinases and immunity: Ancestral molecules with new functions. Immunobiology (2016) 221(3):399&#x2013;411. doi: 10.1016/j.imbio.2015.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.11.014</ArticleId><ArticleId IdType="pubmed">26686909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinteac R, Montalban X, Comabella M. Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurol Neuroimmunol Neuroinflamm (2021) 8(1):e921. doi: 10.1212/NXI.0000000000000921</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000921</ArticleId><ArticleId IdType="pmc">PMC7803328</ArticleId><ArticleId IdType="pubmed">33293459</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch BE, Stougaard J, Spaink HP. Keeping track of the growing number of biological functions of chitin and its interaction partners in biomedical research. Glycobiology (2015) 25(5):469&#x2013;82. doi: 10.1093/glycob/cwv005</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwv005</ArticleId><ArticleId IdType="pmc">PMC4373397</ArticleId><ArticleId IdType="pubmed">25595947</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Goyal A. Chitin and chitinase: Role in pathogenicity, allergenicity and health. Int J Biol Macromol (2017) 97:331&#x2013;8. doi: 10.1016/j.ijbiomac.2017.01.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2017.01.042</ArticleId><ArticleId IdType="pubmed">28093332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen BF, Gray E, Thompson AG, Ansorge O, Anthony DC, Cowley SA, et al. . Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers. Nat Rev Neurol (2021) 17(6):333&#x2013;48. doi: 10.1038/s41582-021-00487-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00487-8</ArticleId><ArticleId IdType="pubmed">33927394</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Th&#xe9;z&#xe9;nas ML, Charles PD, Evetts S, Hu MT, et al. . Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol (2018) 83(2):258&#x2013;68. doi: 10.1002/ana.25143</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo KH, Lee BH, Heo SH, Kim JM, Kim GH, Kim YM, et al. . Allele frequency of a 24&#x2009;bp duplication in exon 10 of the CHIT1 gene in the general Korean population and in Korean patients with gaucher disease. J Hum Genet (2014) 59(5):276&#x2013;9. doi: 10.1038/jhg.2014.16</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2014.16</ArticleId><ArticleId IdType="pubmed">24621582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur N, Perner C, Witte OW, Grosskreutz J. The chitinases as biomarkers for amyotrophic lateral sclerosis: Signals from the CNS and beyond. Front Neurol (2020) 11:377. doi: 10.3389/fneur.2020.00377</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00377</ArticleId><ArticleId IdType="pmc">PMC7267218</ArticleId><ArticleId IdType="pubmed">32536900</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, et al. . Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry (2018) 89(3):239&#x2013;47. doi: 10.1136/jnnp-2017-317138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B, et al. . Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol (2016) 16:173. doi: 10.1186/s12883-016-0689-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-016-0689-x</ArticleId><ArticleId IdType="pmc">PMC5024522</ArticleId><ArticleId IdType="pubmed">27634542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, Pelt J, Talbot K, Benatar M, et al. . CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Trans Neurol (2020) 7(8):1296&#x2013;306. doi: 10.1002/acn3.51114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Halbgebauer S, Witzel S, Verde F, Oeckl P, et al. . Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic lateral sclerosis frontotemporal degeneration (2021) 22(3-4):276&#x2013;86. doi: 10.1080/21678421.2020.1861023</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1861023</ArticleId><ArticleId IdType="pubmed">33576252</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Gromicho M, Pronto-Laborinho A, Almeida C, Gomes RA, Guerreiro ACL, et al. . Cerebrospinal fluid chitinases as biomarkers for amyotrophic lateral sclerosis. Diagnostics (2021) 11(7):1210. doi: 10.3390/diagnostics11071210</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11071210</ArticleId><ArticleId IdType="pmc">PMC8305219</ArticleId><ArticleId IdType="pubmed">34359293</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Sharma A, Mishra P, Vijayalakshmi K, Harsha HC, Sathyaprabha TN, et al. . Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics (2013) 10(1):19. doi: 10.1186/1559-0275-10-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther (2019) 203:107394. doi: 10.1016/j.pharmthera.2019.107394</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.107394</ArticleId><ArticleId IdType="pubmed">31356910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther (2020) 5(1):201. doi: 10.1038/s41392-020-00303-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00303-7</ArticleId><ArticleId IdType="pmc">PMC7490424</ArticleId><ArticleId IdType="pubmed">32929074</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics (2019) 16(7):593&#x2013;600. doi: 10.1080/14789450.2019.1628643</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2019.1628643</ArticleId><ArticleId IdType="pubmed">31195846</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Dom&#xed;nguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging (2021) 13(20):23871. doi:&#xa0;10.18632/aging.203667</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203667</ArticleId><ArticleId IdType="pmc">PMC8580344</ArticleId><ArticleId IdType="pubmed">34738920</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al. . Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry (2019) 90(1):4&#x2013;10. doi: 10.1136/jnnp-2018-318868</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Knorr T, Obermayr F, Bartnik E, Zien A, Aigner T. YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes. Ann Rheum Dis (2003) 62(10):995&#x2013;8. doi: 10.1136/ard.62.10.995</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.10.995</ArticleId><ArticleId IdType="pmc">PMC1754335</ArticleId><ArticleId IdType="pubmed">12972480</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Yang Y, Duan H, He J, Sun L, Hu W, et al. . CHI3L2 is a novel prognostic biomarker and correlated with immune infiltrates in gliomas. Front Oncol (2021) 11:611038. doi: 10.3389/fonc.2021.611038</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.611038</ArticleId><ArticleId IdType="pmc">PMC8084183</ArticleId><ArticleId IdType="pubmed">33937022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilippo C, Longo A, Lazzara F, Cambria D, Distefano G, Palumbo M, et al. . CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients. Mol Cell Neurosci (2017) 85:162&#x2013;9. doi: 10.1016/j.mcn.2017.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2017.10.001</ArticleId><ArticleId IdType="pubmed">28989002</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Gupta PK, Prabhakar S, Sharma S, Thakur K. Analysis of smoking and LPO in ALS. Neurochemistry Int (2014) 71:47&#x2013;55. doi: 10.1016/j.neuint.2014.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.04.004</ArticleId><ArticleId IdType="pubmed">24726768</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR. CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2019) 90(11):1215&#x2013;20. doi: 10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreger M, Steinbach R, Otto M, Turner MR, Grosskreutz J. Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2022) 93(4):422&#x2013;35. doi: 10.1136/jnnp-2021-327503</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327503</ArticleId><ArticleId IdType="pmc">PMC8921583</ArticleId><ArticleId IdType="pubmed">35105727</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Ghosh M, Bhagat SK, Vijayalakshmi K, Preethish-Kumar V, Vengalil S, et al. . Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J Neuroinflamm (2020) 17(1):232. doi: 10.1186/s12974-020-01909-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01909-y</ArticleId><ArticleId IdType="pmc">PMC7412641</ArticleId><ArticleId IdType="pubmed">32762702</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang B, Bi F, Yan LH, Tong J, Huang J, et al. . Profiling the genes affected by pathogenic TDP-43 in astrocytes. J Neurochem (2014) 129(6):932&#x2013;9. doi: 10.1111/jnc.12660</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12660</ArticleId><ArticleId IdType="pmc">PMC4066372</ArticleId><ArticleId IdType="pubmed">24447103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From clinical significance to quantification. Adv Sci (2021) 8(15):e2004433. doi: 10.1002/advs.202004433</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202004433</ArticleId><ArticleId IdType="pmc">PMC8336501</ArticleId><ArticleId IdType="pubmed">34114369</ArticleId></ArticleIdList></Reference><Reference><Citation>Borish LC, Steinke JW. 2. cytokines and chemokines. J Allergy Clin Immunol (2003) 111(2 Suppl):S460&#x2013;75. doi: 10.1067/mai.2003.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mai.2003.108</ArticleId><ArticleId IdType="pubmed">12592293</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol (2017) 17(1):49&#x2013;59. doi: 10.1038/nri.2016.123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.123</ArticleId><ArticleId IdType="pubmed">27916979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranzatelli MR. Advances in biomarker-guided therapy for pediatric- and adult-onset neuroinflammatory disorders: Targeting Chemokines/Cytokines. Front Immunol (2018) 9:557. doi: 10.3389/fimmu.2018.00557</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00557</ArticleId><ArticleId IdType="pmc">PMC5893838</ArticleId><ArticleId IdType="pubmed">29670611</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front Immunol (2017) 8:1005. doi: 10.3389/fimmu.2017.01005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 13(8):722&#x2013;8. doi: 10.1038/ni.2366</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2366</ArticleId><ArticleId IdType="pmc">PMC4158817</ArticleId><ArticleId IdType="pubmed">22814351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, Leoni E, Kuhle J, Tree T, et al. . Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 3(4):e244. doi: 10.1212/NXI.0000000000000244</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, et al. . Humoral factors in ALS patients during disease progression. J Neuroinflamm (2015) 12:127. doi: 10.1186/s12974-015-0350-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, et al. . Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep (2017) 7(1):9094. doi: 10.1038/s41598-017-09097-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in alzheimer&#x2019;s disease, parkinson&#x2019;s disease and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Front Immunol (2018) 9:2122. doi: 10.3389/fimmu.2018.02122</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02122</ArticleId><ArticleId IdType="pmc">PMC6156158</ArticleId><ArticleId IdType="pubmed">30283455</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol (2013) 70(12):1505&#x2013;11. doi: 10.1001/jamaneurol.2013.4646</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4646</ArticleId><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Xia K, Chen L, Fan D. Increased interleukin-6 levels in the astrocyte-derived exosomes of sporadic amyotrophic lateral sclerosis patients. Front Neurosci (2019) 13:574. doi: 10.3389/fnins.2019.00574</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00574</ArticleId><ArticleId IdType="pmc">PMC6560167</ArticleId><ArticleId IdType="pubmed">31231184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J Neurol Sci (2019) 398:50&#x2013;3. doi: 10.1016/j.jns.2019.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats KA, Borchelt DR, Tansey MG, Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol Neurodegener (2022) 17(1):11. doi: 10.1186/s13024-022-00515-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Huo Y, Bai J, Wang H, Wang H, Yang F, et al. . Inflammatory cytokine levels in patients with sporadic amyotrophic lateral sclerosis. Neuro-degenerative Dis (2021) 21(3-4):87&#x2013;92. doi: 10.1159/000522078</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000522078</ArticleId><ArticleId IdType="pubmed">35124669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi N, Kawano Y, Tateishi T, Kikuchi H, Osoegawa M, Ohyagi Y, et al. . Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J Neuroimmunol (2007) 182(1-2):232&#x2013;5. doi: 10.1016/j.jneuroim.2006.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.10.001</ArticleId><ArticleId IdType="pubmed">17097743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. . Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Trans Neurol (2020) 7(7):1103&#x2013;16. doi: 10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Garza MT, Martinez HR, Cruz-Vega DE, Hernandez-Torre M, Moreno-Cuevas JE. Adipsin, MIP-1b, and IL-8 as CSF biomarker panels for ALS diagnosis. Dis Markers (2018) 2018:3023826. doi: 10.1155/2018/3023826</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3023826</ArticleId><ArticleId IdType="pmc">PMC6199888</ArticleId><ArticleId IdType="pubmed">30405855</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martinez L, Calvo AC, Mu&#xf1;oz MJ, Osta R. Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis? Int J Mol Sci (2019) 20(11):2759. doi: 10.3390/ijms20112759</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112759</ArticleId><ArticleId IdType="pmc">PMC6600567</ArticleId><ArticleId IdType="pubmed">31195629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep (2020) 10(1):5941. doi: 10.1038/s41598-020-62756-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest (2017) 127(9):3250&#x2013;8. doi: 10.1172/JCI90607</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Mart&#xed;nez L, de la Torre M, Toivonen JM, Zaragoza P, Garc&#xed;a-Redondo A, Calvo AC, et al. . Circulating cytokines could not be good prognostic biomarkers in a mouse model of amyotrophic lateral sclerosis. Front Immunol (2019) 10:801. doi: 10.3389/fimmu.2019.00801</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00801</ArticleId><ArticleId IdType="pmc">PMC6473074</ArticleId><ArticleId IdType="pubmed">31031774</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Zecca C, Piccininni M, Benmahamed S, Dell&#x2019;Abate MT, Barulli MR, et al. . Plasma inflammatory cytokines are elevated in ALS. Front Neurol (2020) 11:552295. doi: 10.3389/fneur.2020.552295</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9(5):361&#x2013;71. doi: 10.1038/nrc2628</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2628</ArticleId><ArticleId IdType="pubmed">19343034</ArticleId></ArticleIdList></Reference><Reference><Citation>Quessada C, Bouscary A, Ren&#xe9; F, Valle C, Ferri A, Ngo ST, et al. . Skeletal muscle metabolism: Origin or prognostic factor for amyotrophic lateral sclerosis (ALS) development? Cells (2021) 10(6):1449. doi: 10.3390/cells10061449</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061449</ArticleId><ArticleId IdType="pmc">PMC8226541</ArticleId><ArticleId IdType="pubmed">34207859</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti G, Scarlata C, Brambilla L, Rossi D. Tumor necrosis factor alpha in amyotrophic lateral sclerosis: Friend or foe? Cells (2021) 10(3):518. doi: 10.3390/cells10030518</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030518</ArticleId><ArticleId IdType="pmc">PMC8000008</ArticleId><ArticleId IdType="pubmed">33804386</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Dom&#xed;nguez R, Aso E, Povedano M, Ferrer I. Inflammatory gene expression in whole peripheral blood at early stages of sporadic amyotrophic lateral sclerosis. Front Neurol (2017) 8:546. doi: 10.3389/fneur.2017.00546</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00546</ArticleId><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 354(6):610&#x2013;21. doi: 10.1056/NEJMra052723</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra052723</ArticleId><ArticleId IdType="pubmed">16467548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerk SY, Bai Y, Smith J, Lalgudi P, Hunt C, Kuno J, et al. . Homozygous ALS-linked FUS P525L mutations cell- autonomously perturb transcriptome profile and chemoreceptor signaling in human iPSC microglia. Stem Cell Rep (2022) 17(3):678&#x2013;92. doi: 10.1016/j.stemcr.2022.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.01.004</ArticleId><ArticleId IdType="pmc">PMC9039753</ArticleId><ArticleId IdType="pubmed">35120624</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H, Cun&#xed;-L&#xf3;pez C, Stewart R, Colletti T, Notaro A, Nguyen TH, et al. . ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. J Neuroinflamm (2022) 19(1):58. doi: 10.1186/s12974-022-02421-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02421-1</ArticleId><ArticleId IdType="pmc">PMC8887023</ArticleId><ArticleId IdType="pubmed">35227277</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, Karpf L, Bohl D. Neuroinflammation in amyotrophic lateral sclerosis and frontotemporal dementia and the interest of induced pluripotent stem cells to study immune cells interactions with neurons. Front Mol Neurosci (2021) 14:767041. doi: 10.3389/fnmol.2021.767041</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.767041</ArticleId><ArticleId IdType="pmc">PMC8712677</ArticleId><ArticleId IdType="pubmed">34970118</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, et al. . Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci Biobehav Rev (2021) 127:958&#x2013;78. doi: 10.1016/j.neubiorev.2021.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, Simpson EP, Kim SH, Pan T, et al. . Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurolog (2004) 55(2):221&#x2013;35. doi: 10.1002/ana.10805</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N, et al. . CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol (2010) 222(1-2):76&#x2013;81. doi: 10.1016/j.jneuroim.2010.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.03.004</ArticleId><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Gautam M, Kocak N, Xie EF, Mao Q, Bigio EH, et al. . MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J Neuroinflamm (2019) 16(1):196. doi: 10.1186/s12974-019-1589-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId><ArticleId IdType="pmc">PMC6822373</ArticleId><ArticleId IdType="pubmed">31666087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, et al. . Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol (2009) 16(6):771&#x2013;4. doi: 10.1111/j.1468-1331.2009.02560.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behavior (2017) 7(3):e00637. doi: 10.1002/brb3.637</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve (2010) 42(1):95&#x2013;103. doi: 10.1002/mus.21625</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21625</ArticleId><ArticleId IdType="pubmed">20544912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Chen Y, Shang H. Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Trans Neurodegener (2021) 10(1):3. doi: 10.1186/s40035-020-00228-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00228-9</ArticleId><ArticleId IdType="pmc">PMC7792103</ArticleId><ArticleId IdType="pubmed">33419478</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Matsui N, Fujita K, Miyashiro A, Nodera H, Izumi Y, et al. . Increased proinflammatory cytokines in sera of patients with multifocal motor neuropathy. J Neurolog Sci (2014) 346(1-2):75&#x2013;9. doi: 10.1016/j.jns.2014.07.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.07.059</ArticleId><ArticleId IdType="pubmed">25130929</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill FR. Interferons. Lancet (1989) 1(8646):1060&#x2013;3. doi: 10.1016/S0140-6736(89)92455-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)92455-0</ArticleId><ArticleId IdType="pubmed">2469921</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gao L, Zang D. Elevated levels of IFN-&#x3b3; in CSF and serum of patients with amyotrophic lateral sclerosis. PloS One (2015) 10(9):e0136937. doi: 10.1371/journal.pone.0136937</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136937</ArticleId><ArticleId IdType="pmc">PMC4557946</ArticleId><ArticleId IdType="pubmed">26332465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity (2019) 50(4):907&#x2013;23. doi: 10.1016/j.immuni.2019.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.025</ArticleId><ArticleId IdType="pmc">PMC6839410</ArticleId><ArticleId IdType="pubmed">30995506</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin KR, Wong HL, Witko-Sarsat V, Wicks IP. G-CSF - a double edge sword in neutrophil mediated immunity. Semin Immunol (2021) 54:101516. doi: 10.1016/j.smim.2021.101516</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101516</ArticleId><ArticleId IdType="pubmed">34728120</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Matsui N, Fujita K, Nodera H, Shimizu F, Miyamoto K, et al. . CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol Neuroimmunol Neuroinflamm (2015) 2(5):e138. doi: 10.1212/NXI.0000000000000138</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000138</ArticleId><ArticleId IdType="pmc">PMC4529282</ArticleId><ArticleId IdType="pubmed">26280014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Biundo F, Stanley ER. Colony stimulating factors in the nervous system. Semin Immunol (2021) 54:101511. doi: 10.1016/j.smim.2021.101511</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101511</ArticleId><ArticleId IdType="pmc">PMC8671346</ArticleId><ArticleId IdType="pubmed">34743926</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell (2019) 176(6):1248&#x2013;64. doi: 10.1016/j.cell.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId><ArticleId IdType="pmc">PMC6410740</ArticleId><ArticleId IdType="pubmed">30849371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhou S, Cai H, Gong Z, Zang D. VEGF levels in CSF and serum in mild ALS patients. J Neurolog Sci (2014) 346(1-2):216&#x2013;20. doi:&#xa0;10.1016/j.jns.2014.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.08.031</ArticleId><ArticleId IdType="pubmed">25204587</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima T, Kobashi S, Watanabe Y, Nakanishi M, Honda N, Katagi M, et al. . Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing mesenchymal stem cells for ALS in mice. iScience (2020) 23(11):101764. doi:&#xa0;10.1016/j.isci.2020.101764</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101764</ArticleId><ArticleId IdType="pmc">PMC7677706</ArticleId><ArticleId IdType="pubmed">33251493</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa M, Derynck R, Miyazono K. TGF-&#x3b2; and the TGF-&#x3b2; family: Context-dependent roles in cell and tissue physiology. Cold Spring Harbor Perspect Biol (2016) 8(5):a021873. doi:&#xa0;10.1101/cshperspect.a021873</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a021873</ArticleId><ArticleId IdType="pmc">PMC4852809</ArticleId><ArticleId IdType="pubmed">27141051</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati M, Crippa V, Rusmini P, Cristofani R, Messi E, Piccolella M, et al. . Multiple roles of transforming growth factor beta in amyotrophic lateral sclerosis. Int J Mol Sci (2020) 21(12):4291. doi:&#xa0;10.3390/ijms21124291</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124291</ArticleId><ArticleId IdType="pmc">PMC7352289</ArticleId><ArticleId IdType="pubmed">32560258</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, Kim S, Cui X, Zheng L, Oh SJ, Anderson T, et al. . Transforming growth factor beta (TGF-&#x3b2;) is a muscle biomarker of disease progression in ALS and correlates with smad expression. PloS One (2015) 10(9):e0138425. doi:&#xa0;10.1371/journal.pone.0138425</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138425</ArticleId><ArticleId IdType="pmc">PMC4574401</ArticleId><ArticleId IdType="pubmed">26375954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D, Contreras O, Rebolledo DL, Espinoza JP, van Zundert B, Brandan E. ALS skeletal muscle shows enhanced TGF-&#x3b2; signaling, fibrosis and induction of fibro/adipogenic progenitor markers. PloS One (2017) 12(5):e0177649. doi: 10.1371/journal.pone.0177649</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177649</ArticleId><ArticleId IdType="pmc">PMC5433732</ArticleId><ArticleId IdType="pubmed">28520806</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrillo MG, Ronchetti S, Ricci E, Alunno A, Gerli R, Nocentini G, et al. . GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev (2015) 14(2):117&#x2013;26. doi: 10.1016/j.autrev.2014.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.10.011</ArticleId><ArticleId IdType="pubmed">25449679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, et al. . Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res (2015) 2015:171520. doi: 10.1155/2015/171520</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/171520</ArticleId><ArticleId IdType="pmc">PMC4413981</ArticleId><ArticleId IdType="pubmed">25961057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, et al. . Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener (2018) 13(1):60. doi: 10.1186/s13024-018-0292-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. . Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: A study of humans and a transgenic mouse model. JAMA Neurol (2018) 75(6):681&#x2013;9. doi: 10.1001/jamaneurol.2018.0035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayakawa Y, Sakumi K, Kajitani K, Kadoya T, Horie H, Kira J, et al. . Galectin-1 deficiency improves axonal swelling of motor neurones in SOD1(G93A) transgenic mice. Neuropathol Appl Neurobiol (2015) 41(2):227&#x2013;44. doi: 10.1111/nan.12123</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12123</ArticleId><ArticleId IdType="pubmed">24707896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez Hern&#xe1;ndez E, Alanis Olvera B, Carmona Gonz&#xe1;lez D, Guerrero Mar&#xed;n O, Pantoja Mercado D, Valencia Gil L, et al. . Neuroinflammation and galectins: a key relationship in neurodegenerative diseases. Glycoconjugate J (2022) 39(5):685&#x2013;99. doi: 10.1007/s10719-022-10064-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10719-022-10064-w</ArticleId><ArticleId IdType="pubmed">35653015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Steyn FJ, Huang L, Mantovani S, Pfluger CM, Woodruff TM, et al. . Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. J Neurolog Sci (2015) 357(1-2):22&#x2013;7. doi: 10.1016/j.jns.2015.06.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, et al. . Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci: Off J Soc Neurosci (2006) 26(9):2467&#x2013;73. doi: 10.1523/JNEUROSCI.5253-05.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5253-05.2006</ArticleId><ArticleId IdType="pmc">PMC6793668</ArticleId><ArticleId IdType="pubmed">16510725</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;bitz WR, Kr&#xfc;ger C, Pitzer C, Weber D, Laage R, Gassler N, et al. . A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metabol: Off J Int Soc Cereb Blood Flow Metab (2008) 28(1):29&#x2013;43. doi: 10.1038/sj.jcbfm.9600496</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600496</ArticleId><ArticleId IdType="pubmed">17457367</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsmane B, Aebischer J, Moumen A, Raoul C. Cerebrospinal fluid-targeted delivery of neutralizing anti-IFN&#x3b3; antibody delays motor decline in an ALS mouse model. Neuroreport (2014) 25(1):49&#x2013;54. doi: 10.1097/WNR.0000000000000043</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0000000000000043</ArticleId><ArticleId IdType="pubmed">24145774</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, Cassina P, Otsmane B, Moumen A, Seilhean D, Meininger V, et al. . IFN&#x3b3; triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death Differ (2011) 18(5):754&#x2013;68. doi: 10.1038/cdd.2010.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2010.143</ArticleId><ArticleId IdType="pmc">PMC3131923</ArticleId><ArticleId IdType="pubmed">21072055</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen S, Budeus B, Peters S, Iberl S, Meyer AL, Kammermaier T, et al. . (Filgrastim) response in ALS patients. Front Neurol (2018) 9:971. doi: 10.3389/fneur.2018.00971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00971</ArticleId><ArticleId IdType="pmc">PMC6275232</ArticleId><ArticleId IdType="pubmed">30534107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther (2005) 5(12):1635&#x2013;46. doi: 10.1517/14712598.5.12.1635</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.5.12.1635</ArticleId><ArticleId IdType="pubmed">16318427</ArticleId></ArticleIdList></Reference><Reference><Citation>Powanda MC, Moyer ED. A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury. Inflammopharmacology (2021) 29(3):897&#x2013;901. doi: 10.1007/s10787-021-00820-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00820-z</ArticleId><ArticleId IdType="pmc">PMC8139218</ArticleId><ArticleId IdType="pubmed">34019218</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak A, Agrawal A. Evolution of c-reactive protein. Front Immunol (2019) 10:943. doi: 10.3389/fimmu.2019.00943</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00943</ArticleId><ArticleId IdType="pmc">PMC6503050</ArticleId><ArticleId IdType="pubmed">31114584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsuchou H, Kastin AJ, Mishra PK, Pan W. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Biochem: Int J Exp Cell Physiol Biochem (2012) 30(5):1109&#x2013;19. doi: 10.1159/000343302</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343302</ArticleId><ArticleId IdType="pmc">PMC4099000</ArticleId><ArticleId IdType="pubmed">23018453</ArticleId></ArticleIdList></Reference><Reference><Citation>Custodero C, Ciavarella A, Panza F, Gnocchi D, Lenato GM, Lee J, et al. . Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. GeroScience (2022) 44(3):1373&#x2013;92. doi: 10.1007/s11357-022-00556-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00556-w</ArticleId><ArticleId IdType="pmc">PMC9213626</ArticleId><ArticleId IdType="pubmed">35486344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem (2011) 117(3):528&#x2013;37. doi: 10.1111/j.1471-4159.2011.07224.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07224.x</ArticleId><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, et al. . Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve (2010) 42(1):104&#x2013;11. doi: 10.1002/mus.21683</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21683</ArticleId><ArticleId IdType="pmc">PMC2975276</ArticleId><ArticleId IdType="pubmed">20583124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharel S, Ojha R, Preethish-Kumar V, Bhagat R. C-reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review. Brain Behavior (2022) 12(3):e2532. doi: 10.1002/brb3.2532</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2532</ArticleId><ArticleId IdType="pmc">PMC8933772</ArticleId><ArticleId IdType="pubmed">35201675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, et al. . Serum c-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol (2017) 74(6):660&#x2013;7. doi: 10.1001/jamaneurol.2016.6179</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Sun J, Pawitan Y, Piehl F, Chen H, Ingre C, et al. . Creatinine and c-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and parkinson&#x2019;s disease. Brain Commun (2020) 2(2):fcaa152. doi:&#xa0;10.1093/braincomms/fcaa152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa152</ArticleId><ArticleId IdType="pmc">PMC7850290</ArticleId><ArticleId IdType="pubmed">33543134</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDevanter DR, Heltshe SL, Skalland M, West NE, Sanders DB, Goss CH, et al. . C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response. J cystic fibrosis: Off J Eur Cystic Fibrosis Soc (2021) 21(4):588&#x2013;93. doi: 10.1016/S1569-1993(21)01582-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1569-1993(21)01582-4</ArticleId><ArticleId IdType="pmc">PMC9206040</ArticleId><ArticleId IdType="pubmed">34933824</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. . Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm (2015) 2(3):e100. doi: 10.1212/NXI.0000000000000100</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecomte M, Cou&#xeb;delo L, Meugnier E, Loizon E, Plaisanci&#xe9; P, Durand A, et al. . Soybean polar lipids differently impact adipose tissue inflammation and the endotoxin transporters LBP and sCD14 in flaxseed vs. palm oil-rich diets. J Nutr Biochem (2017) 43:116&#x2013;24. doi: 10.1016/j.jnutbio.2017.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2017.02.004</ArticleId><ArticleId IdType="pubmed">28284063</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, Thonhoff JR, Thome AD, Faridar A, et al. . Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep (2020) 10(1):15295. doi: 10.1038/s41598-020-72247-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al. . Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurolog Scand (2009) 119(6):383&#x2013;9. doi: 10.1111/j.1600-0404.2008.01112.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2008.01112.x</ArticleId><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Thonhoff JR, Faridar A, Thome AD, Zhao W, Wen S, et al. . Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS. Ann Neurol (2022) 92(2):195&#x2013;200. doi: 10.1002/ana.26375</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26375</ArticleId><ArticleId IdType="pmc">PMC9545429</ArticleId><ArticleId IdType="pubmed">35445431</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho AC, Gromicho M, Pereira M, Pinto S, Barros MDA, Swash M, et al. . Plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis. Acta Neurolog Scand (2018) 137(2):233&#x2013;7. doi: 10.1111/ane.12851</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12851</ArticleId><ArticleId IdType="pubmed">28967121</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Streich L, Pinto S, Pronto-Laborinho A, Nimtz M, Conradt HS, et al. . Exploring cerebrospinal fluid IgG n-glycosylation as potential biomarker for amyotrophic lateral sclerosis. Mol Neurobiol (2019) 56(8):5729&#x2013;39. doi: 10.1007/s12035-019-1482-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1482-9</ArticleId><ArticleId IdType="pubmed">30674035</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotrophic lateral sclerosis frontotemporal degeneration (2018) 19(5-6):362&#x2013;76. doi: 10.1080/21678421.2018.1433689</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1433689</ArticleId><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty L, Henderson RD, McCombe PA, Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotrophic lateral sclerosis frontotemporal degeneration (2020) 21(7-8):631&#x2013;4. doi: 10.1080/21678421.2020.1779303</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779303</ArticleId><ArticleId IdType="pubmed">32558599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Santos C, Gomes C, Fernandes A, Correia AM, Sebasti&#xe3;o AM, et al. . Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage. Mol Neurobiol (2018) 55(5):4207&#x2013;24. doi:&#xa0;10.1007/s12035-017-0631-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0631-2</ArticleId><ArticleId IdType="pubmed">28612258</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Cunha C, Barbosa M, Vaz AR, Brites D. Exosomes from NSC-34 cells transfected with hSOD1-G93A are enriched in miR-124 and drive alterations in microglia phenotype. Front Neurosci (2017) 11:273. doi: 10.3389/fnins.2017.00273</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00273</ArticleId><ArticleId IdType="pmc">PMC5434170</ArticleId><ArticleId IdType="pubmed">28567000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Gomes C, Vaz AR, Brites D. Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. Mediators Inflamm (2016) 2016:6986175. doi: 10.1155/2016/6986175</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6986175</ArticleId><ArticleId IdType="pmc">PMC5209629</ArticleId><ArticleId IdType="pubmed">28096568</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, et al. . Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol (2015) 77(1):75&#x2013;99. doi: 10.1002/ana.24304</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24304</ArticleId><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N, Grant R. Kynurenine pathway metabolism and neuroinflammatory disease. Neural Regener Res (2017) 12(1):39&#x2013;42. doi: 10.4103/1673-5374.198971</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.198971</ArticleId><ArticleId IdType="pmc">PMC5319230</ArticleId><ArticleId IdType="pubmed">28250737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Brew BJ, Guillemin GJ. Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem (2011) 118(5):816&#x2013;25. doi: 10.1111/j.1471-4159.2010.07159.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07159.x</ArticleId><ArticleId IdType="pubmed">21182524</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, et al. . The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotoxicity Res (2010) 18(2):132&#x2013;42. doi: 10.1007/s12640-009-9129-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9129-7</ArticleId><ArticleId IdType="pubmed">19921535</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheykhansari S, Kozielski K, Bill J, Sitti M, Gemmati D, Zamboni P, et al. . Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review. Cell Death Dis (2018) 9(3):348. doi: 10.1038/s41419-018-0379-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0379-2</ArticleId><ArticleId IdType="pmc">PMC5832817</ArticleId><ArticleId IdType="pubmed">29497049</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta neurologica Scandinavica (2003) 107(6):412&#x2013;8. doi: 10.1034/j.1600-0404.2003.00076.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00076.x</ArticleId><ArticleId IdType="pubmed">12757473</ArticleId></ArticleIdList></Reference><Reference><Citation>Edri-Brami M, Sharoni H, Hayoun D, Skutelsky L, Nemirovsky A, Porgador A, et al. . Development of stage-dependent glycans on the fc domains of IgG antibodies of ALS animals. Exp Neurol (2015) 267:95&#x2013;106. doi: 10.1016/j.expneurol.2015.02.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.02.023</ArticleId><ArticleId IdType="pubmed">25725350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Satoh M, Sumi H, Fujimura H, Tohyama C, Yanagihara T, et al. . Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur J Neurosci (2001) 13(7):1363&#x2013;70. doi: 10.1046/j.0953-816x.2001.01512.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0953-816x.2001.01512.x</ArticleId><ArticleId IdType="pubmed">11298796</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, et al. . Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet (2013) 22(20):4127&#x2013;35. doi: 10.1093/hmg/ddt261</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt261</ArticleId><ArticleId IdType="pmc">PMC3781640</ArticleId><ArticleId IdType="pubmed">23740943</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Baranek T, Vourc&#x2019;h P, Nadal-Desbarats L, Goossens JF, Marouillat S, et al. . Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: Deleterious alteration of lipid metabolism. Neurother: J Am Soc Exp NeuroTher (2016) 13(4):905&#x2013;17. doi: 10.1007/s13311-016-0461-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0461-3</ArticleId><ArticleId IdType="pmc">PMC5081117</ArticleId><ArticleId IdType="pubmed">27444617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wen Y, Wang L, Wen L, You W, Wei S, et al. . Therapeutic opportunities of interleukin-33 in the central nervous system. Front Immunol (2021) 12:654626. doi: 10.3389/fimmu.2021.654626</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.654626</ArticleId><ArticleId IdType="pmc">PMC8165230</ArticleId><ArticleId IdType="pubmed">34079543</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen P, Pollari E, Kanninen KM, Savchenko E, Lehtonen &#x160;, Wojciechowski S, et al. . Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. IBRO Rep (2019) 6:74&#x2013;86. doi: 10.1016/j.ibror.2019.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibror.2019.01.005</ArticleId><ArticleId IdType="pmc">PMC6348738</ArticleId><ArticleId IdType="pubmed">30705990</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie T, Fang H, Ouyang W, Angart P, Chiang MJ, Bhirde AA, et al. . The ELISA detectability and potency of pegfilgrastim decrease in physiological conditions: Key roles for aggregation and individual variability. Sci Rep (2020) 10(1):2476. doi: 10.1038/s41598-020-59346-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-59346-z</ArticleId><ArticleId IdType="pmc">PMC7016140</ArticleId><ArticleId IdType="pubmed">32051479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Savchenko E, Jaronen M, Kanninen K, Malm T, Wojciechowski S, et al. . Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflamm (2011) 8:74. doi: 10.1186/1742-2094-8-74</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-74</ArticleId><ArticleId IdType="pmc">PMC3146845</ArticleId><ArticleId IdType="pubmed">21711557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, He Y, Li KC, Zhou X. A system mathematical model of a cell-cell communication network in amyotrophic lateral sclerosis. Mol BioSyst (2013) 9(3):398&#x2013;406. doi: 10.1039/c2mb25370d</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2mb25370d</ArticleId><ArticleId IdType="pmc">PMC3752652</ArticleId><ArticleId IdType="pubmed">23287963</ArticleId></ArticleIdList></Reference><Reference><Citation>Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P, et al. . Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology (2021) 162(2):160&#x2013;78. doi: 10.1111/imm.13264</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13264</ArticleId><ArticleId IdType="pmc">PMC7808166</ArticleId><ArticleId IdType="pubmed">32939758</ArticleId></ArticleIdList></Reference><Reference><Citation>Keifer OP, Jr., O&#x2019;Connor DM, Boulis NM. Gene and protein therapies utilizing VEGF for ALS. Pharmacol Ther (2014) 141(3):261&#x2013;71. doi: 10.1016/j.pharmthera.2013.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.10.009</ArticleId><ArticleId IdType="pmc">PMC4659499</ArticleId><ArticleId IdType="pubmed">24177067</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Bracci PM, Azhir A, Barohn R, Bedlack R, et al. . Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. Muscle Nerve (2022) 66(1):39&#x2013;49. doi: 10.1002/mus.27511</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27511</ArticleId><ArticleId IdType="pmc">PMC9327716</ArticleId><ArticleId IdType="pubmed">35098554</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, et al. . NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotrophic lateral sclerosis frontotemporal degeneration (2014) 15(7-8):601&#x2013;9. doi: 10.3109/21678421.2014.951940</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951940</ArticleId><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Riepsaame J, van Oudenaren A, den Broeder BJ, van Ijcken WF, Pothof J, Leenen PJ. MicroRNA-mediated down-regulation of m-CSF receptor contributes to maturation of mouse monocyte-derived dendritic cells. Front Immunol (2013) 4:353. doi: 10.3389/fimmu.2013.00353</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00353</ArticleId><ArticleId IdType="pmc">PMC3812696</ArticleId><ArticleId IdType="pubmed">24198819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Meininger V, Guillemin GJ. Recent advances in the treatment of amyotrophic lateral sclerosis. emphasis on kynurenine pathway inhibitors. Nerv Syst Agent Med (2009) 9(1):32&#x2013;9. doi: 10.2174/187152409787601941</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152409787601941</ArticleId><ArticleId IdType="pubmed">20021336</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. . Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm (2018) 5(4):e465. doi: 10.1212/NXI.0000000000000465</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Oh KW, Jin HK, Bae JS. Immune inflammatory modulation as a potential therapeutic strategy of stem cell therapy for ALS and neurodegenerative diseases. BMB Rep (2018) 51(11):545&#x2013;6. doi: 10.5483/BMBRep.2018.51.11.255</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2018.51.11.255</ArticleId><ArticleId IdType="pmc">PMC6283021</ArticleId><ArticleId IdType="pubmed">30463642</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. . Panel of oxidative stress and inflammatory biomarkers in ALS: A pilot study. Can J neurological Sci Le J canadien Des Sci neurologiques (2017) 44(1):90&#x2013;5. doi: 10.1017/cjn.2016.284</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.284</ArticleId><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. . Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2013) 5(1):64&#x2013;79. doi: 10.1002/emmm.201201544</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Ren CH, Wada M, Kawanami T. Galectin-1 as a potential therapeutic agent for amyotrophic lateral sclerosis. Curr Drug Target (2005) 6(4):407&#x2013;18. doi: 10.2174/1389450054021846</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450054021846</ArticleId><ArticleId IdType="pubmed">16026259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancinella A, Mancinella M, Carpinteri G, Bellomo A, Fossati C, Gianturco V, et al. . Is there a relationship between high c-reactive protein (CRP) levels and dementia? Arch gerontology geriatrics (2009) 49 Suppl 1:185&#x2013;94. doi: 10.1016/j.archger.2009.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2009.09.028</ArticleId><ArticleId IdType="pubmed">19836632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>